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Abstract
Background—Breast cancer (BC) disparities may widen with genomic advances. We compared 
non-Hispanic white (NHW), Black, and Hispanic BC survivors for: 1) cancer risk management 
practices (CRM) among BRCA carriers; and 2) provider discussion and receipt of genetic testing.
Methods—A population-based sample of NHW, Black, and Hispanic women diagnosed with 
invasive BC ≤ age 50 in 2009–2012 were recruited through the state cancer registry. Using 
multiple logistic regression we compared CRM in BRCA carriers and association of demographic 
and clinical variables with provider discussion and receipt of testing.
Results—Of the 1622 participants, 36.1% (159/440) Blacks, 64.5% (579/897) NHW, 49.6% 
(58/117) Spanish-speaking Hispanics, and 69.0% (116/168) English-speaking Hispanics had 
BRCA testing, of whom 90 had a pathogenic BRCA mutation. Among BRCA carriers, RRM and 
RRSO rates were significantly lower among Blacks compared to Hispanics and NHW after 
controlling clinical and demographic variables (p=0.025 and 0.008, respectively). Compared to 
NHW, discussion of genetic testing with a provider was 16 times less likely among Blacks 
(p<0.0001) and nearly two times less likely among Spanish-speaking Hispanics (p=0.04) after 
controlling clinical and sociodemographic factors.
Conclusions—Our results suggest lower rates of RRSO among Black compared to Hispanic and 
NHW BRCA carriers, which is concerning as benefits from genetic testing arise from CRM 
options. Furthermore, lower BRCA testing rates among Blacks may partially be due to lower 
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likelihood of provider discussion. Future studies are needed to improve cancer risk identification 
and management practices across all populations to prevent the widening of disparities.
Introduction
Breast cancer (BC) is the most common cancer among women in the United States, with 5–
10% due to inherited gene mutations most commonly in the BRCA1 and BRCA2 (BRCA) 
genes.1, 2 BRCA mutation carriers have a 60–70% lifetime risk of BC and up to a 44% risk 
of ovarian cancer,3–6 compared to 12% and <2% for women in the general population. 
Furthermore, the risk of a second primary BC among BRCA mutation carriers may be over 
50%, particularly among those who develop their first BC at an early age.7, 8 These risks 
may be reduced by 90% or more (i.e., to below that of the general population) through 
preventive options such as risk-reducing mastectomy (RRM) and risk-reducing salpingo-
oophorectomy (RRSO).9, 10 Once an individual is tested for and identified to have inherited 
cancer predisposition, they will only reap health benefits from acting on this information. 
Consequently, clinical practice guidelines in the United States (US) for BRCA carriers have 
been developed through the National Comprehensive Cancer Network (NCCN) including: 1) 
annual BC surveillance (through mammogram and breast MRI) or RRM for BC risk 
management; and 2) RRSO for ovarian cancer risk management.11
Prior efforts to explore cancer risk management practices among BRCA carriers have 
primarily been based on non-Hispanic White (NHW) populations at academic 
institutions12–15 or integrated health systems.16 Studies among US-based women 
consistently suggest higher rates of RRSO (~70%) than RRM (~40%).12–16 Yet no prior 
efforts have compared cancer risk management across ethnically and racially diverse 
populations with BRCA mutations, treated across varied settings.
Identification of a BRCA mutation has potential to empower women with options to detect 
cancers early or prevent them altogether.17–19 Yet only ~10% of those with BRCA mutations 
in the US are aware they carry a mutation.20 Furthermore, there are substantial disparities 
across populations in awareness and utilization of genetic testing for inherited BC, with 
considerably lower rates reported among Blacks and Hispanics compared to NHW.21–24 Per 
NCCN guidelines, all women diagnosed with BC ≤50 should be offered cancer genetic risk 
assessment (which includes genetic counseling and consideration for testing),11 yet few 
discuss testing with their healthcare provider.25–28
Through a population-based sample of young Black, Hispanic, and NHW women with BC, 
we sought to compare: 1) cancer risk management practices among BRCA carriers; and 2) 
provider discussion and receipt of genetic testing.
Methods
Participants
Eligible participants were women diagnosed with invasive BC ≤50 between the years 2009–
2012 living in Florida at the time of diagnosis, and alive at the time of recruitment. Through 
protocols approved through the Institutional Review Boards at the University of South 
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Florida and the Florida Department of Health, recruitment of Black women was initiated in 
2012 as previously described, 29, 30 and that of White and Hispanic women was initiated in 
2014. Using information on all eligible participants released by the Florida State Cancer 
Registry, contact was attempted among all Black and Hispanic women in the sampling frame 
and in a random sample of White women (Figure 1).
Participants were recruited using previously described state-mandated recruitment 
methods,29, 30 which consisted of 2 mailings, 3 weeks apart, including a ‘telephone response 
card’ to give potential participants the option to either decline (i.e., indicating they did not 
wish to be contacted by phone) or express interest in participation with follow-up by a study 
team member. If no response was received within 3 weeks of the second mailing, a member 
of the study team attempted to contact the potential participant by telephone to explain the 
study and determine interest in participation. For those willing to participate, written 
informed consent was obtained and a baseline study questionnaire was completed.
Measures
Clinical (i.e., age at diagnosis, stage of diagnosis, histologic subtype, tumor receptor status) 
and demographic (i.e., primary payer at diagnosis, race/ethnicity) data were obtained from 
the cancer registry for all potential participants meeting inclusion criteria. Tumor receptor 
status was coded as triple negative (TN) if registry data indicated the tumor was negative for 
all three receptors (ER, PR, and HER2) and non-triple negative (non-TN) if at least one of 
these receptors was present. Tumors that were missing data for one or more receptors, but 
were negative for the other receptors were categorized as undetermined. For all participants 
in the undetermined group, clarification was attempted through medical record verification 
and patient self-report. Data obtained through the baseline questionnaire included healthcare 
provider discussion of genetic testing for inherited cancer risk, and receipt of BRCA testing. 
Medical record verification was attempted in all participants who indicated receipt of BRCA 
testing in whom a signed a medical release was available. Participants were categorized 
through self-reported race/ethnicity into NHW, Black, and Hispanic groups. Hispanics were 
further categorized as Spanish-speaking (if they spoke Spanish at home) or English-speaking 
(all others). Additional information obtained through the baseline questionnaire included: 
partner status, biological children, income, family cancer history, education, insurance status 
and cancer risk management (including receipt of an RRSO, RRM; and high-risk BC 
screening (mammograms and breast MRIs).
Data Analysis
Demographic and clinical characteristics available through the cancer registry for all eligible 
participants were summarized for each racial/ethnic strata using descriptive statistics. 
Consented participants in each racial/ethnic strata were compared to all other presumed 
eligible women from the cancer registry using Pearson’s chi-square tests. For participants in 
each of the four racial/ethnic groups, demographic and clinical characteristics were 
summarized and compared using Pearson’s chi-square tests for categorical variables and 
Mann-Whitney test for continuous variables.
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Among those with a known BRCA mutation at the time of the baseline questionnaire, 
proportions with RRSO, RRM and breast surveillance were calculated based on self-report. 
Comparisons between Blacks, Hispanics and NHW were made using multiple logistic 
regression to control for age at enrollment, time since diagnosis, income, family history of 
breast and ovarian cancer, and private insurance at diagnosis. Analyses were conducted 
using SAS version 9.4. The goodness-of-fit for all regression models was evaluated by the 
Hosmer-Lemeshow statistic. For all analyses, a two-sided p-value of <0.05 was considered 
statistically significant.
Proportion who discussed genetic testing with a healthcare provider and proportion who 
underwent genetic testing were calculated for each racial/ethnic strata. Two multiple logistic 
regression models were then conducted using the 1,325 cases for whom all data were 
available. The first regression model evaluated racial/ethnic differences in genetic testing 
discussion and the second model evaluated receipt of genetic testing. To simultaneously 
control for key variables and evaluate the relative strength of relationship between the two 
outcomes (i.e., discussed testing and receipt of testing), a path model was conducted using 
Mplus version 6.12. Variables with a p-value <0.15 from the two logistic regression models 
were included in the model as follows. Race/ethnicity, having children, diagnosed at or 
below age 45, annual income over $25,000, college educated, family history of breast 
cancer, and having private insurance were included as predictors of having testing. 
Simultaneously, race/ethnicity, having children, triple negative tumor, diagnosed at or below 
age 45, annual income over $25,000, college educated, family history of breast cancer, 
family history of ovarian cancer, having private insurance, and years from diagnosis to 
survey were included as predictors for receipt of testing. A direct path was included to 
evaluate the strength of relationship between discussed testing and receipt of testing while 
controlling for all other variables specified in the path model.
Results
Participants included a total of 1622 BC survivors, consisting of 440 Blacks, 168 English-
speaking Hispanics, 117 Spanish-speaking Hispanics, and 897 NHW (Figure 1). 
Comparisons between participants and all others within each respective racial/ethnic strata 
revealed no statistically significant differences with regard to median age, stage, histologic 
subtype, marital status, or employment at diagnosis (results not shown). Among those 
reporting genetic testing, medical record verification was obtained in 72% overall, and 78% 
of BRCA carriers. Participants differed across racial/ethnic strata on several clinical and 
demographic variables (Table 1).
Among NHW, Black and Hispanic BRCA carriers, uptake of: 1) RRSO was 76.6%, 28.1%, 
and 90.9%, respectively; 2) RRM was 95.7%, 68.8%, and 81.8%, respectively; and 3) 
guideline-based BC screening or RRM was 100%, 85.7%, and 100%, respectively (Figure 
2). Among BRCA carriers with remaining breast tissue who reported no breast screening, 2 
had not yet completed their BC treatment, both of whom were Black. With Blacks as the 
referent group, even after controlling for possible confounders, Hispanics and NHW 
remained significantly more likely to have RRSO (p=0.025) and RRM (p=0.008). Hosmer-
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Lemeshow tests provided evidence of adequate model fit for all logistic regression models 
(all p>0.05).
All participants met national guidelines for genetic risk assessment and counseling;31 
however, among Blacks, Spanish-speaking Hispanics, English-speaking Hispanics and 
NHW, the proportion who reported: 1) having discussed genetic testing with a provider was 
37.3%, 70.1%, 85.7% and 85.7%, respectively; and 2) receipt of genetic testing was 36.1%, 
49.6%, 69.05%, and 64.55%, respectively. Compared to NHW, Blacks were 16.6 times less 
likely to have discussed genetic testing with a healthcare provider (p<0.0001) and Spanish-
speaking Hispanics were nearly two times less likely to have discussed testing (p=0.04) after 
controlling for other variables (Table 2). Rates of genetic testing discussion were similar 
among NHW and primarily English-speaking Hispanics.
Blacks were 5.6 times less likely to have had genetic testing than NHW when controlling for 
other variables (Table 2), but differences between NHW and Spanish-speaking Hispanics 
were no longer significant (p=0.82) after controlling for clinical and socioeconomic 
differences. The path model reveals the strongest association with receipt of testing is having 
a healthcare provider discuss testing (Figure 3).
Discussion
To our knowledge, this is the first study to compare differences in cancer risk management 
practices across an ethnically and racially diverse sample of BRCA mutation carriers tested 
and treated across multiple settings. Our findings suggest lower rates of RRSO and RRM 
among Blacks. Furthermore, our results demonstrate lower genetic testing rates among 
Blacks compared to NHW, most strongly associated with lower genetic testing discussions 
by healthcare providers.
When considering BRCA testing, it is important to recognize that benefits do not arise from 
BRCA testing itself, but rather acting on test results to detect cancers early or prevent them 
altogether. A number of studies have evaluated cancer risk management practices among 
BRCA carriers; however, these primarily encompass NHW populations mainly based at 
academic institutions12–15 or integrated health systems.16 A recent retrospective cohort 
study of primarily NHW BRCA carriers from a community healthcare system in Northern 
California reported uptake of RRSO and RRM among BRCA carriers of 74% and 44%, 
respectively,16 which is slightly higher than that recently reported from US-based academic 
centers.12, 15 Similarly, uptake of preventive options reported through an international study 
of BRCA carriers reported RRSO and RRM rates of 71.1% and 36.3%, respectively, among 
US-based women.13 Taken together, these RRSO rates are similar to those found in our 
study among NHW and Hispanics, yet substantially higher than the RRSO rate of 28% 
observed among Blacks in our study. Consistent with the low RRSO rates we observed 
among Blacks are results from African American BRCA carriers in which breast and 
ovarian cancer surveillance was preferred over risk-reducing surgery, however this earlier 
study was based on a single African American kindred.32 Consequently, our study represents 
the first to evaluate and compare follow-up care among unselected BRCA carriers across 
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minority populations, with results suggesting substantial racial differences in cancer risk 
management practices.
Although RRSO remains the only reliable option for ovarian cancer risk management among 
BRCA carriers, RRM or heightened screening through annual MRI and mammograms are 
both considered appropriate options for BC risk management.11 However, adherence to 
screening over time among unaffected BRCA carriers in an integrated healthcare system 
identified low compliance with annual MRI (35%) and mammograms (43%) at baseline 
among those without RRM with compliance at 5 years dropping to only 3% and 7%, 
respectively.16 More recently, a follow-up study of primarily NHW BRCA carriers who 
received genetic counseling and BRCA testing through an academic center indicated 51% 
had RRM and 72% had RRSO.33 Interestingly, despite the limited number of minorities in 
this study (~11%; n=11), study authors reported both white race and higher BC genetics 
knowledge to be significantly associated with adherence to recommended management, 
highlighting the potential for genomic testing to widen existing disparities among minority 
populations. Ultimately, our study is the sole population-based effort to compare differences 
in cancer risk management practices across minority BRCA carriers treated across diverse 
settings, underscoring the need for further studies to confirm and address observed 
disparities in follow-up care.
The majority of BRCA testing has occurred in Caucasian populations,24, 34–37 with 
disproportionately lower rates among Blacks and Hispanics,23, 24, 37 consistent with our 
results among Blacks and Spanish-speaking Hispanics. However, English-speaking 
Hispanics and NHW had similar testing rates which may reflect acculturation of Hispanics 
over generations. Black women in our study were not recent immigrants and did not have a 
language barrier, yet their testing rates were the lowest demonstrating a concerning health 
disparity that requires focused attention. This is particularly alarming given that limited 
studies among high risk Hispanics38–41 and Blacks42 suggest high interest in these services 
once it is explained to them.
Reasons for lower testing rates among Blacks and Hispanics include both lower awareness 
about genetic testing21 and access to cancer genetics experts,43 geographic barriers,44 
language barriers,45 and socioeconomic factors such as insurance, education and income.46 
In fact, the presence of private insurance had a direct impact on both genetic testing 
discussion and receipt of testing in the path model (Figure 3). Based on our own clinical 
experience this is not surprising because private insurers tend to be more likely to cover 
genetic testing than Medicaid. Additionally, a genetic test discussion may not even occur if 
testing is not perceived to be feasible by patients or providers, as might be the case if the 
patient is uninsured or on Medicaid. In our study, even after controlling for socioeconomic 
factors, Blacks were less likely to be tested but the single strongest predictor was provider 
discussion of genetic testing. Consequently, in addition to patient-level factors, provider and 
system level factors may contribute to suboptimal testing rates among minorities. In 
particular, multiple studies demonstrate the importance of healthcare provider 
recommendations in receipt of genetic testing, with lack of physician referral amongst the 
most highly cited barriers to testing among BC survivors. 23, 35, 47–50 Our findings that 
healthcare provider discussion of testing was the strongest predictor for receipt of BRCA 
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testing with lowest rates of both testing discussion and testing receipt among Blacks, is 
consistent with prior studies. Although not explored through our study, other potential 
explanations for observed differences include provider characteristics and distribution, as 
well as variability in clinical practice situations, which should be explored further through 
future efforts. Ultimately, our findings are concerning and suggest the need for the 
development of multi-level interventions targeted at both the patient and provider level in 
order to successfully address the widening disparities due to genomic advances.
The current study has several strengths including the first population-based design to 
systematically compare cancer risk management practices among BRCA carriers drawn 
from an ethnically and racially diverse sample of BC survivors treated across multiple 
settings, enhancing the generalizability of our findings. Furthermore, our estimates of 
provider discussion and genetic testing across diverse populations provides updated and 
novel data, compared to prior efforts with limited minority representation, non-population 
based sampling, or sampling frame of women diagnosed before 2008. 23, 35, 47–50 
Furthermore, BRCA testing confirmation in over 72% of all cases further strengthens the 
accuracy and validity of our observations.
Despite these strengths, there remain some limitations including our inability to fully 
determine reasons for the observed differences in uptake of cancer risk management options 
and testing rates across populations. Furthermore, although participants were diagnosed 
within the same 4 years and eligibility criteria were the same, the Blacks and non-Blacks 
were recruited under separate protocols. However, time since diagnosis and age at diagnosis 
(or age at the time of the survey) were included in the models in order to minimize bias. 
Furthermore, our study is cross-sectional and represents a single snapshot in time, thus 
longitudinal follow-up is critical to determine whether these disparities persist or widen. As 
well, given the time between diagnosis and recruitment, there is potential for recall bias. 
Moreover, our sample size of carriers was limited, given that they represented a subset 
drawn from a much larger unselected population of BC survivors. Nevertheless, we observed 
clear differences in uptake of RRSO and RRM among Black carriers, which requires 
confirmation and additional longitudinal follow-up. Additionally, survey completion rates 
across racial subgroups was below 30% which may lead to selection bias, although the study 
population was comparable to the source population based on available clinical and 
demographic variables. As well, the sample was confined to Florida, thus may not be 
generalizable to other parts of the country where clinical practices may vary. Finally, all 
participants were diagnosed prior to a number of practice changing events that occurred 
around 2013 and beyond, including: plummeting sequencing costs due to technological 
advances in conjunction with the fall of the BRCA patent, implementation of the Affordable 
Care Act, and celebrity disclosures.51, 52 To determine if these changes impacted 
populations with existing health disparities, more recent studies across ethnically and 
racially diverse populations of high risk patients are needed, as was recently identified as a 
research gap by the US Preventive Services Task Force (USPSTF).53
Ultimately, it is critical to better understand the reasons for the lower uptake of cancer risk 
management options among Black BRCA carriers, in order to develop interventions and 
assure access to preventive care. In this regard, coverage for genetic testing does not equate 
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to coverage for preventive care, which is essential to improve health outcomes.54 
Consequently, variations in preventive services coverage may exacerbate health disparities 
without policies to ensure equitable access to these services. Given that BRCA testing and 
cancer risk management are choices, it remains imperative to identify and discuss genetic 
testing with high risk patients across all populations, communicate the information in a 
culturally congruent and understandable way, and ensure access to testing and follow-up 
care regardless of socioeconomic factors.
In summary, our study is the first to demonstrate differences in cancer risk management 
across Blacks, Hispanics and NHW recruited through population-based efforts. The lower 
RRSO rates observed among Black BRCA carriers are particularly concerning given that 
most ovarian cancers are diagnosed at a later stage without reliable means for early 
detection. Furthermore, our findings demonstrate that healthcare provider discussion was the 
strongest predictor of testing. Taken together, the underlying etiology of differences 
observed in testing rates and follow-up care require further study to identify facilitators and 
barriers such as psychological, cultural and geographic factors. In addition to patient-
specific factors, provider and system-level factors must be examined to develop solutions to 
narrow existing health disparities in gene-based care. Ultimately, multi-level interventions 
are needed to reduce the growing healthcare disparities in clinical cancer genetics.
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